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IMPLEMENTATION AND OPERATIONAL RESEARCH: CLINICAL SCIENCE
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Versus Mogen Clamp for Early Infant Male
Circumcision in Zimbabwe
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Background: Early infant male circumcision (EIMC) is a potential
key HIV prevention intervention, providing it can be safely and
efﬁciently implemented in sub-Saharan Africa. Here, we present
results of a randomized noninferiority trial of EIMC comparing the
AccuCirc device with Mogen clamp in Zimbabwe.
Methods: Between January and June 2013, eligible infants were
randomized to EIMC through either AccuCirc or Mogen clamp
conducted by a doctor, using a 2:1 allocation ratio. Participants were
followed for 14 days post-EIMC. Primary outcomes for the trial were
EIMC safety and acceptability.
Results: One hundred ﬁfty male infants were enrolled in the trial
and circumcised between 6 and 54 days postpartum (n = 100
AccuCirc; n = 50 Mogen clamp). Twenty-six infants (17%) were
born to HIV-infected mothers. We observed 2 moderate adverse
events (AEs) [2%, 95% conﬁdence interval (CI): 0.2 to 7.0] in the
AccuCirc arm and none (95% CI: 0.0 to 7.1) in the Mogen clamp
arm. The cumulative incident risk of AEs was 2.0% higher in the
AccuCirc arm compared with the Mogen Clamp arm (95% CI: 20.7
to 4.7). As the 95% CI excludes the predeﬁned noninferiority margin
of 6%, the result provides evidence of noninferiority of AccuCirc
compared with the Mogen clamp. Nearly all mothers (99.5%)
reported great satisfaction with the outcome. All mothers, regardless
of arm said they would recommend EIMC to other parents, and
would circumcise their next son.
Conclusions: This ﬁrst randomized trial of AccuCirc versus
Mogen clamp for EIMC demonstrated that EIMC using these
devices is safe and acceptable to parents. There was no difference
in the rate of AEs by device.
Key Words: AccuCirc, early infant male circumcision, HIV, Mogen
clamp, Zimbabwe
(J Acquir Immune Deﬁc Syndr 2015;69:e156–e163)
INTRODUCTION
Early infant male circumcision (EIMC, performed
within the ﬁrst 60 days of life) is recommended by the
World Health Organization (WHO) and UNICEF for pre-
vention of HIV.1,2 Although EIMC’s effects on HIV will take
longer to realize, infant circumcision is likely to ultimately be
more effective at preventing HIV acquisition than adult
voluntary medical male circumcision (VMMC) as the pro-
cedure is performed long before the individual becomes
sexually active. This eliminates the possibility of resuming
sexual activity before complete wound healing and the
associated risk of HIV acquisition or transmission.3 Resump-
tion of sex before the recommended postcircumcision
abstinence period (6 weeks) is a major issue with adult
men.4–7 In the 3 randomized controlled trials conducted in
sub-Saharan Africa, 3.9% of participants reported early sex
in Kenya, 5.4% in Uganda, and 22.5% in South Africa.4,7–9
More recently in an observational study conducted in
Zambia, 24% of circumcised men reported resuming sex
earlier than the recommended postcircumcision abstinence
period (6 weeks).5
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Research has shown that VMMC is a cost-saving
intervention, with modeling studies conducted between
2009 and 2011 estimating that if 80% of males aged 15–49
years were circumcised in 14 priority countries within 5 years
and that coverage was sustained at this rate thereafter, 3.4
million new HIV infections could be averted within 15 years,
in addition to yielding savings of US $16.5 billion in care and
treatment costs.10–12 A modeling study conducted in Rwanda
in 2008 suggested that infant male circumcision is less costly
than adolescent and adult VMMC and renders greater
dividends despite the time lag between the procedure and
averted infections.13,14 It has been concluded that providing
universal access to male circumcision, including infant MC,
in conjunction with other effective HIV prevention interven-
tions, will reduce the overall cost of HIV epidemics driven by
heterosexual transmission.13
There are currently 3 circumcision devices that have
been prequaliﬁed by WHO for use in infants: Gomco clamp,
Mogen clamp, and Plastibell.15 Each of these devices is
characterized by rare, but potentially serious complications:
(1) a mismatch in sizes of the separate pieces of the Gomco
clamp can result in laceration of the glans penis,15,16 (2)
circumcision using the Mogen clamp can result in partial or
total amputation of the glans penis or removal of too little
foreskin (in which case the remaining foreskin remains
vulnerable to infection with HIV),15,17–19 and (3) migration
of the Plastibell during circumcision can result in necrosis of
the glans and other injuries; this risk is increased if the
incorrect size of “bell” is used.15,20–22 A relatively new EIMC
device, AccuCirc, has the potential to address some of these
shortcomings in that it comes prepackaged and does not
require assembly. It has a shielding ring that protects the glans
penis preventing laceration or amputation.16 In addition,
AccuCirc is disposable negating the need for device sterili-
zation and facilitating its use at remote health care centers.16
In addition, AccuCirc can be safely applied by non–surgically
trained nurse-midwives.16
Here, we present results of a randomized noninferiority
trial of EIMC comparing the AccuCirc device with Mogen
clamp conducted in Zimbabwe. Because the cost and logistics
of the AccuCirc device were perceived to be superior to the
Mogen Clamp, a noninferiority trial design was chosen to
determine whether AccuCirc was no worse with respect to
adverse events (AEs). The results of this trial are part of
a series of studies to determine safety, acceptability, and
feasibility of using AccuCirc in resource-limited settings and
will be used to inform device prequaliﬁcation with WHO and
EIMC scale-up in Zimbabwe and the wider region.
METHODS
Study Design
This individually randomized noninferiority trial evalu-
ated the hypothesis that the AccuCirc device was as safe as that
of a WHO prequaliﬁed EIMC device—Mogen clamp. The
study design was based on the WHO Framework for Clinical
Evaluation of Male Circumcision Devices.23 Participants were
randomized to AccuCirc or Mogen clamp in a 2:1 ratio and
were followed for 2 weeks postcircumcision. Primary out-
comes for the trial were EIMC safety and acceptability.
Recruitment and Training of EIMC Providers
Between November and December 2012, 4 doctors
were recruited and trained in the use of the AccuCirc and
Mogen clamp devices by 2 expert trainers. The trainers
previously helped with drafting of the WHO Manual for
Early Infant Male Circumcision under Local Anaesthesia15
and oversaw training and ﬁeld-testing of EIMC devices
(including Mogen clamp and AccuCirc) in Nigeria and
Botswana. The Zimbabwe training curriculum consisted of
didactic lectures, practical skill sessions, use of an EIMC
anatomic model, written assessment, and practical evaluation.
Trainees were required to score 100% on the written
assessment and show competency using the anatomic model.
Each provider then had to demonstrate competency while
performing 5 supervised circumcisions with each device.
Participants
Mothers and infants were enrolled between January and
June 2013 at Edith Opperman, a Harare polyclinic with
approximately 400 deliveries per month.24 Sensitization on
EIMC and participant recruitment took place at the antenatal
clinic and after delivery in the maternity ward. Educational
materials (posters and pamphlets) and demand creation
activities (road shows, dramas, group and interpersonal
discussions) were used to educate and sensitize the commu-
nity about the trial. Before discharge postdelivery, mothers
who were interested in having their male infants circumcised
were asked to (1) provide locator information and consent for
an outreach worker to physically verify their address, (2)
complete an interviewer-administered questionnaire (asked
among others: sociodemographic information, HIV and MC
knowledge), and (3) discuss the procedure with their male
partner (if relevant) before attending for EIMC at their ﬁrst
postnatal visit. Information on the number of eligible mothers
approached about EIMC was recorded.
Locator data were physically veriﬁed on all potential
trial participants between recruitment and enrollment. Mater-
nal eligibility criteria were ability to attend follow-up
appointments at study clinic until 2 weeks postpartum,
preparedness to provide locator information and to be visited
at home between delivery and circumcision, and provision of
written informed consent. Mothers who were incarcerated
were excluded. Initially, only infants aged 6–10 days were
eligible for inclusion. However, after recruiting 108 babies,
eligibility was extended to include babies aged 6–60 days in
line with WHO guidance.15 Additional infant eligibility
criteria were as follows: male, gestational age $36 weeks,
birth weight $2500 g, no evidence of neonatal infection/
sepsis or other illness requiring hospitalization, no family
history of bleeding disorder, and no genital abnormality
representing a contraindication to EIMC. These eligibility
criteria had been used previously in trials that compared
Mogen clamp with other devices in Botswana and Zam-
bia.20,25 Data on eligibility criteria were collected from all
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mothers and infants. Data on mother’s HIV status were also
collected. All infants who were ineligible due to genital
abnormalities were referred to a specialist.
Sample Size
The sample size of 150 subjects (100 in AccuCirc arm;
50 in Mogen clamp arm) was guided by the WHO
Framework for Clinical Evaluation of Male Circumcision
Devices.23 This sample size provides 80% power to detect
noninferiority, based on a 2-sided 95% conﬁdence interval
(CI) approach, a 2% risk of AE in the Mogen clamp arm, and
a noninferiority margin of 6% failure between the 2 arms. A
noninferiority margin of 6% was chosen because this was
deemed the maximum difference in safety that would be
acceptable in terms of public health.
Randomization
Infants who met the trial inclusion criteria were
randomized to infant male circumcision using either the
AccuCirc device or the Mogen clamp in a 2:1 ratio (sample
size 100 AccuCirc; 50 Mogen clamp). Randomization was
conducted using randomly selected block sizes of 3, 6, or 9
generated off site in Stata version 13 (College Station, TX).
Randomization codes were kept at the study site in
sequentially numbered opaque envelopes.
Intervention
Before enrollment, study staff performed a physical
examination to exclude infants with abnormalities precluding
circumcision. All circumcisions were performed by the 4
trained doctors on a rotational basis. They were assisted by 3
nurse-midwives. All procedures were conducted under asep-
tic conditions (using sterile devices, gloves, drapes, swabs).
All infants received vitamin K to minimize bleeding; vitamin
K should be routinely administered at birth but was out of
stock nationally at the time of the trial and therefore had to be
imported speciﬁcally for that purpose. In addition, all infants
had approximately 1 g of EMLA cream (eutectic mixture of
local anesthetics containing 2.5% lidocaine and 2.5% prilo-
caine) applied to the outer foreskin and shaft of the penis
about 45 minutes before the procedure. When EMLA cream
had achieved anesthetic effect, the surgical area was cleaned
with povidone–iodine. Achievement of anesthetic effect was
determined by clamping the foreskin using artery forceps. If
there was no pain response from the infant, subsequent steps
would commence. Otherwise, providers would wait until the
EMLA cream had achieved anesthetic effect (additional 10–
15 minutes). The circumcision site (around the corona) was
then marked using a surgical pen mark. The surgical pen mark
served to minimize excessive or insufﬁcient skin removal.
Physiologic adhesions between the foreskin and the glans
were released.
Device-speciﬁc procedures were used to expose the penile
glans. During the procedure, glucose water was given using
a gloved ﬁnger as per previous recommendations.26–28 EIMC
using AccuCirc was performed in line with manufacturer’s
recommendations (www.accucirc.com), and as recommended
by the study previously conducted in Botswana.16 The 2
AccuCirc sizes (1.1 and 1.3 cm penile diameter) were used.
EIMC using Mogen clamp was performed as outlined in the
WHO manual15 and as recommended by the studies pre-
viously conducted in Botswana,20 Kenya,17 and Zambia.25
After the procedure, the circumcision wound was dressed and
infants were checked for postprocedure bleeding or other
immediate complications. Mothers were given detailed post-
procedure care instructions (how to deal with dressing,
bleeding, and signs of infection) and emergency contact
information. Mothers were encouraged to phone the nurse
coordinator or attend the clinic in the event of any worries or
unanticipated events that occurred between scheduled visits.
Follow-up and Evaluation
Follow-up appointments at the clinic took place at days
2, 7, and 14 postcircumcision. At these visits, parents were
asked about complications. The infants also had a physical
exam, including inspection of the circumcision site, by the
EIMC doctors.
Outcomes
Primary end points for the comparative trial were EIMC
safety and acceptability. These outcomes have been pre-
viously measured in trials that compared Mogen clamp with
other devices in Botswana and Zambia.20,25 Safety was
measured by the number of moderate and severe AEs related
to each EIMC technique. EIMC-related AEs were categorized
as bleeding, infection, inadequate or excessive skin removal,
and penile injury (glans, urethra, or shaft) (Table 1). Minor
events such as bleeding that could be stopped with simple
compression were recorded but excluded from analyses.
EIMC acceptability was deﬁned as the proportion of parents
(1) who adopted EIMC for their son, (2) who reported being
satisﬁed with the procedure by EIMC technique, and (3) who
expressed willingness to adopt EIMC for a future son. A
numerical scale (0–10) was used to evaluate the level of
parental satisfaction; this was analyzed as a binary outcome
with not satisﬁed deﬁned as a score of ,6. A numerical scale
(0–10) was also used to record parental recommendations
about circumcision to friends or relatives; a score of 0 was
classiﬁed as “would not recommend” and 10 as “would
deﬁnitely recommend.” Secondary outcomes were as follows:
(1) time required for each EIMC technique (measured using
a stopwatch plus video recording of each procedure), (2)
proportion with complete wound healing at 14 days post-
circumcision for each EIMC technique, and (3) safety
stratiﬁed by infant HIV exposure status.
Statistical Analyses
Statistical analyses were performed using Stata 13.
Noninferiority was evaluated for the cumulative incident risk
of AEs. The difference in cumulative incident risk of AEs for
the 2 treatment arms was calculated and so was an associated
2-sided 95% CI to assess noninferiority of the AccuCirc
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procedure. The primary analyses were intention to treat.
Superiority in the AccuCirc arm compared with the Mogen
clamp arm was evaluated for (1) AEs resulting from the
procedure, (2) time taken to perform the procedure, (3)
wound healing, and (4) parental assessment of the procedure
and its consequences (including satisfaction with the cos-
metic result). The effect estimate for AEs (outcome 1) and
time for procedure (outcome 2) was the mean difference, and
95% CIs were calculated. For binary outcomes (wound
healing and parental satisfaction), the proportion in each
study arm was calculated and compared. Logistic regression
was used to calculate an odds ratio and associated 95% CI.
Differences in participant characteristics were compared
between arms.
Ethical Considerations
The study was approved by the Medical Research
Council of Zimbabwe and the ethics committees of University
College London and the London School of Hygiene and
Tropical Medicine. Written informed consent was obtained
from the infant’s mother and verbal consent from infant’s
father (if relevant) before participant enrollment. After the
procedure, mothers received a 20-L plastic bucket, 2 bars of
washing soap, a 100-mL bottle of Vaseline (for wound care),
and 3 disposable nappies (total value US $8). In addition, at
each scheduled clinic visit, mothers received US $5 for bus
fare reimbursement.
RESULTS
Participant Flow
To enroll 150 babies in the comparative trial, we
approached 1151 parents of newborn male infants, corre-
sponding to a 13% uptake of EIMC. A total 984 (85%)
parents declined for their son to participate. Parental reasons
for nonadoption of EIMC included fear of harm and
sociocultural considerations.29 A further 17 male infants
were excluded after assessing their eligibility for inclusion
(Fig. 1). One hundred ﬁfty male infants aged 6–54 days were
circumcised between January and June 2013. All were
circumcised according to their allocated intervention (n =
100 AccuCirc; n = 50 Mogen clamp). All participants
attended the 3 scheduled follow-up visits on days 2, 7,
and 14.
Infant and Mothers Characteristics
The median gestation, birth weight, and body temper-
ature were 40 weeks, 3.2 kg, and 36.4°C respectively, and
similar by trial arm (Table 2). Twenty-six infants (17%) were
born to HIV-infected mothers. The mean age at circumcision
was 8 days and was similar in both arms. The majority of
mothers (63%) were aged 25 years or older, married (93%),
and had completed secondary education (80%); these char-
acteristics were similar between trial arms.
Adverse Events
The AccuCirc device was deemed to be of correct size
in all 100 AccuCirc procedures. There were 2 moderate AEs
in the AccuCirc arm (2%; 95% CI: 0.2 to 7.0) (Table 3).
These were 1 case of excess skin removal (hydrocortisone
cream applied and wound was completely healed 4 months
post-EIMC); and 1 case of inadequate skin removal, which
warranted corrective surgery and was completely healed 20
days postcorrective surgery. No AEs occurred in the Mogen
clamp arm. The cumulative incident risk of AEs was thus
2.0% higher in the AccuCirc arm compared with the Mogen
Clamp arm (95% CI: 20.7 to 4.7). As the 95% CI excludes
the noninferiority margin of 6%, the result provides evidence
of noninferiority of AccuCirc compared with the Mogen
clamp. Furthermore, the 95% CI includes zero, providing
little evidence that Mogen clamp is superior to AccuCirc. The
comparative safety of the AccuCirc and Mogen devices was
similar in those infants either exposed to HIV or not (P =
0.42), although there was low power for this comparison.
During provider training, on 1 occasion, the AccuCirc
device made only a partial incision (cut approximately 70% of
TABLE 1. Classification of Moderate and Severe AEs (Adapted
with permission From VMMC AE Action Guide)
Moderate Severe
Bleeding Bleeding that is not
controlled by new
dressings or 5–10 min of
manual pressure, and
requires a special return to
the clinic for a pressure
dressing, additional skin
sutures, or vitamin K
administration without
surgical re-exploration of
the wound
Bleeding that requires
surgical re-exploration,
hospitalization, or
transfer to another
facility or any case
where blood transfusion
or intravenous ﬂuid is
necessary
Infection Discharge from the wound,
painful swelling with
erythema, or elevated
temperature or use of oral
antibiotics
Cellulitis or abscess of the
wound, or infection
severe enough to require
surgical intervention,
hospitalization, or
intravenous or
intramuscular antibiotic
therapy
Inadequate skin
removal
Prepuce partially covers
glans when ﬂaccid but
surgical correction is not
necessary
Prepuce partially covers
glans when ﬂaccid and
surgical correction is
necessary
Excess skin
removal
Tightness of the skin
discernible and additional
sutures or skin
mobilization needed for
wound closure, but no
other intervention needed
Reoperation or referral/
transfer to another
facility required
Injury to penis Signiﬁcant laceration
requiring prolonged
follow-up, care and
attention, or repeated/
additional dressings
Signiﬁcant injury including
laceration or severed
portion of glans, damage
to the urethra or shaft
laceration with ongoing
bleeding that requires
hospitalization, transfer,
or transfusion
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prepuce circumference), which was successfully completed
using a pair of sterile surgical scissors. No partial cuts were
encountered during the comparative trial. Because the partial
cut occurred during training rather than during the trial, it was
not included in trial analyses (although it was recorded and
reported as an “incident”).
Wound healing was complete in 144/150 boys by day
14 postcircumcision; 94% of the infants circumcised by the
AccuCirc device and all infants circumcised by Mogen clamp
had healed by day 14 (Table 3). The 6 infants with incomplete
wound healing at day 14 included the 2 infants with moderate
AEs, 2 infants with minor adhesions, which occurred post-
EIMC, and 2 infants with delayed wound healing due to poor
wound care. The mean time taken to perform the procedure
was 15.5 minutes and was similar in both arms [mean
difference = 0.1 minute (95% CI: 21.2 to 1.4)].
FIGURE 1. Trial participants recruitment and follow-up.
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Parental Satisfaction
Parental satisfaction with the circumcision procedure
was assessed at the 2-day postcircumcision visit. The mother
was present at this visit in 100% of cases, and in addition,
the father attended this visit for 17% of boys (Table 3).
Nearly all mothers (99.5%) reported being satisﬁed with
the outcome (score 6–10), and this was similar between
arms. The most common reasons for dissatisfaction among
mothers were wound care requirements (n = 5, 3%), pain
(n = 3, 2%), and babies crying (n = 3, 2%). All mothers
who answered the relevant questions, regardless of arm
said they would recommend EIMC to other parents and
would circumcise their next newborn son (response rate
at least 98%). Among the 25 fathers who reported satisfac-
tion with the procedure, 100% gave a score of 6–10. Wound
care requirement was the most common reason for dissat-
isfaction among fathers. All fathers would recommend
the procedure to a friend and all fathers would have a future
son circumcised.
DISCUSSION
We have conducted the ﬁrst randomized trial of
AccuCirc versus Mogen clamp for EIMC and found that
EIMC using these devices is safe, feasible, and acceptable to
parents. There was no difference in the rate of AEs by device.
We observed 2 moderate AEs (2%, 95% CI: 0.4 to 7.7)
in the AccuCirc arm and none (95% CI: 0.0 to 7.1) in the
Mogen clamp arm during the trial. The 2 AEs resolved
quickly and without any lasting disability. Furthermore,
because the 95% CI for the mean difference in AE
percentages (20.7 to 4.7) excludes the noninferiority margin
of 6%, we conclude that the AccuCirc device is noninferior
compared with the Mogen clamp. In the single-arm study
conducted with the AccuCirc device in Botswana, re-
searchers also observed 1 moderate AE (post-EIMC
bleeding that lasted 90 minutes).16 Moreover, these AEs
were experienced earlier on in the trial and so it is possible
that they were due to doctors’ relatively limited experience
of using the AccuCirc device at this stage. We have learnt
from the VMMC program that the rate of AEs falls as
providers gain greater proﬁciency.30 The AccuCirc device
AE rate will be more accurately quantiﬁed in a larger (n =
500) follow-up ﬁeld study that has been conducted in the
same study population. Nonetheless, the fact that AccuCirc
poses the potential for partial circumcisions warrants
further investigation.
Acceptability of the procedure by actual uptake was
lower than previously suggested by hypothetical acceptability
studies (13% versus 60%),31,32 although the latter was among
all adults and not necessarily those who are actually going to
have children in the future. Our ﬁndings on the mismatch
between hypothetical and actual EIMC acceptability are
consistent with those from another regional setting. In a study
conducted in Zambia, although 97% of mothers who
participated in a quantitative survey indicated that they
deﬁnitely or probably planned to have their newborn son
circumcised, only 11% of participants subsequently brought
their newborn sons for infant circumcision.33 However, in
both Zambia and Zimbabwe, EIMC was offered within
a research setting. EIMC uptake within a research setting,
and in Zimbabwe in the context of a trial, may be different
from that when EIMC is offered as part of a programme. In
addition, Zimbabwean parents were informed that the trial
was comparing 2 EIMC devices. Parents may therefore, have
felt this indicated that the devices were “experimental”; this
thought may have exacerbated their fear of harm. Further-
more, the hesitancy of some cultural groups to participate in
research has been documented.34,35
Of note, Zimbabwe is traditionally a noncircumcising
country. It is inevitable that it will take time and the
programme will need to earn the trust of parents before
EIMC—a novel and invasive procedure—becomes accepted.
Nonetheless, culturally appropriate demand–creation activi-
ties to promote EIMC need to be developed and introduced if
EIMC is to become universal.36 In practice, however,
sustained acceptability and uptake will depend on perceptions
of the safety and aesthetic aspects of the procedure.37
Encouragingly, in this trial, nearly all mothers (99.5%)
reported satisfaction with the outcome. These ﬁndings are
consistent with those from other regional settings (Bot-
swana,20 Kenya,38 and Zambia25) that have also shown high
levels of satisfaction with the EIMC outcome (.90%).16,25
With speciﬁc reference to satisfaction with EIMC performed
through AccuCirc, the ﬁndings are consistent with those from
Botswana where 91% of mothers reported high or complete
satisfaction with the outcome.16 To maintain these high levels
of satisfaction within EIMC programs, EIMC provision will
TABLE 2. Infant and Mothers Characteristics
AccuCirc Device
(N = 100)
Mogen Clamp
(N = 50)
Infant characteristics
Median baby’s weight in
kilograms (min–max)
3.2 (2.5–4.8) 3.2 (2.5–4.4)
Median gestational age in weeks
(min–max)
40 (36–41) 40 (37–41)
Median baby temperature in
degree Celsius (min–max)
36.4 (36–37.2) 36.4 (36–37.3)
Infant exposure to HIV, % 18 (18) 8 (16)
Age of baby, d
Median (min–max) 8 (6–54) 8 (6–52)
6–10, % 83 (83) 41 (82)
11–30, % 12 (12) 7 (14)
31–54, % 5 (5) 2 (4)
Mothers characteristics, %
Mothers age, yrs
,25 37 (37) 18 (36)
$25 63 (63) 32 (64)
Married 91 (91) 48 (96)
Live with male partner 89 (89) 47 (94)
Completed secondary level
education
83 (83) 37 (74)
Ethnic group, %
Shona 91 (91) 46 (92)
Non-Shona 9 (9) 4 (8)
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need to be carefully supervised and monitored to ensure (1)
a good cosmetic result and (2) that AEs are prevented.32
Limitations
Although the trial sample size was guided by the WHO
Framework for Clinical Evaluation of Male Circumcision
Devices,23 it was small. It is therefore possible that we did not
detect all potential AEs that might occur during EIMC rollout.
The follow-up ﬁeld study undertaken in 500 infants will
enhance our understanding of AEs associated with the
procedure. Also, we only explored actual acceptability of
doctor-led EIMC. Because it is likely that EIMC rollout will
be through nurse-midwives, it is unclear how or whether this
will affect uptake. Future research needs to explore actual
acceptability of nurse-midwife delivered EIMC to effectively
inform EIMC programming and rollout.
CONCLUSIONS
We safely circumcised 150 infants in a randomized trial
of AccuCirc versus Mogen clamp for EIMC in Zimbabwe.
TABLE 3. Primary and Secondary Outcomes After Circumcision and Time Taken for the Procedure
AccuCirc Device (N = 100),
n (%)
Mogen Clamp (N = 50),
n (%)
Crude Effect Estimate
(95% CI)
AEs, wound healing, and time of procedure, %
All AEs* 2 (2) 0 (0) Mean difference = 2.0 (20.7 to 4.7)
All AEs stratiﬁed by infant HIV exposure status†
Infant not exposed to HIV 1/81 (1.2) 0/42 (0) Mean difference = 1.2 (22.1 to 4.6)
Infant exposed to HIV 1/18 (5.6) 0/8 (0) Mean difference = 5.5 (211.8 to 23.0)
Complete wound healing at day 14 94 (94) 50 (100) Inestimable
Time taken to perform procedure 15.6 min 15.5 min Mean difference = 0.1 min (21.2 to 1.4)
Mothers satisfaction, %
Mothers satisﬁed with procedure‡ 99 (99) 50 (100) Inestimable
Satisfaction score (0–10)
#5 1 (1) 0 (0)
6–8 2 (2) 3 (6)
9 7 (7) 2 (4)
10 90 (90) 45 (90)
Reasons for dissatisfaction
Appearance 0 (0) 0 (0)
Wound care requirements 3 (3) 2 (4)
Complication 0 (0) 0 (0)
Delay in discharge 0 (0) 0 (0)
Other reason§ 7 (7) 3 (3)
Mother would recommend MCk 98 (100) 50 (100) Inestimable
Mother would have next son circumcised¶ 99 (100) 50 (100) Inestimable
Fathers satisfaction, %
Father present at the 2-day follow-up visit# 19 (19) 6 (12)
Fathers satisﬁed with procedure** 19 (100) 6 (100) Inestimable
Father satisfaction score
7 1 (5) 1 (17)
8 2 (11) 0 (0)
10 16 (84) 5 (83)
Reason for dissatisfaction
Wound care 0 1
Incomplete wound healing 1 0
Father would deﬁnitely recommend MC 19 (100) 6 (100)
Would have a future son circumcised 19 (100) 6 (100)
*Adverse events included: severe bleeding, infection, inadequate or excessive skin removal, and penile injury.
†HIV exposure status unknown for 1 infant in the AccuCirc arm who was delivered at home.
‡Satisfaction score of 6–10.
§In the AccuCirc arm, reasons were baby cried (n = 2), pain (n = 2), wound not completely healed (n = 1), minimal pain (n = 1), and not sure (n = 1). In the Mogen clamp arm,
reasons were fear (n = 1), baby cried (n = 1), and pain (n = 1).
kTwo mothers did not answer this question in the AccuCirc arm.
¶One mother did not answer this question in the AccuCirc arm.
#The number and % fathers that were present at the 2-day follow-up visit and responded to questions about satisfaction himself; others responses about the fathers satisfaction came
from the mothers or another person in attendance (ie, not the baby’s father himself).
**Among the 25 fathers who reported their satisfaction.
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The AccuCirc device has the potential to facilitate widespread
scale-up of safe EIMC in sub-Saharan Africa.
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